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Abstract 
Background 
Prospective efficacy monitoring of anti-malarial treatments is imperative for timely detection 
of resistance development. The in vivo efficacy of artesunate-amodiaquine (ASAQ) fixed-
dose combination (FDC) was compared to that of artemether-lumefantrine (AL) among 
children aged six to 59 months in Nimba County, Liberia, where Plasmodium falciparum 
malaria is endemic and efficacy data are scarce. 
Methods 
An open-label, randomized controlled non-inferiority trial compared the genotyping adjusted 
day 42 cure rates of ASAQ FDC (ASAQ Winthrop®) to AL (Coartem®) in 300 children 
aged six to 59 months with uncomplicated falciparum malaria. Inclusion was between 
December 2008 and May 2009. Randomization (1:1) was to a three-day observed oral 
regimen (ASAQ: once a day; AL: twice a day, given with fatty food). Day 7 
desethylamodiaquine and lumefantrine blood-concentrations were also measured. 
Results 
The day 42 genotyping-adjusted cure rate estimates were 97.3% [95%CI: 91.6-99.1] for 
ASAQ and 94.2% [88.1-97.2] for AL (Kaplan-Meier survival estimates). The difference in 
day 42 cure rates was −3.1% [upper limit 95%CI: 1.2%]. These results were confirmed by 
observed proportion of patients cured at day 42 on the per-protocol population. Parasite 
clearance was 100% (ASAQ) and 99.3% (AL) on day 3. The probability to remain free of re-
infection was 0.55 [95%CI: 0.46-0.63] (ASAQ) and 0.66 [0.57-0.73] (AL) (p = 0.017). 
Conclusions 
Both ASAQ and AL were highly efficacious and ASAQ was non-inferior to AL. The 
proportion of patients with re-infection was high in both arms in this highly endemic setting. 
In 2010, ASAQ FDC was adopted as the first-line national treatment in Liberia. Continuous 
efficacy monitoring is recommended. 
Trial registration 
The protocols were registered with Current Controlled Trials, under the identifier numbers 
ISRCTN51688713, ISRCTN40020296. 
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Background 
Despite notable decreases in malaria incidence rates in various endemic settings, Plasmodium 
falciparum malaria remains a serious public health problem especially for the African 
continent [1]. Potent artemisinin-containing combination therapy (ACT) is the recommended 
first-line treatment for uncomplicated falciparum malaria in most endemic countries [2]. This 
includes artesunate-amodiaquine (AS + AQ), artemether-lumefantrine (AL), artesunate-
mefloquine (AS-MQ), artesunate-sulfadoxine-pyrimethamine (AS-SP) and 
dihydroartemisinin-piperaquine (DHAPQ), which are considered efficacious and safe [2-5]. 
Fixed-dose combinations (FDC) should be used whenever possible to support adherence. The 
first FDC of AS + AQ (ASAQ Winthrop®) was developed by the Drugs for Neglected 
Diseases initiative (DNDi), and is currently registered in 32 African countries. ASAQ FDC 
was shown to be efficacious, safe and well tolerated in previous studies [6-9]. 
Prospective periodic monitoring of the efficacy of anti-malarial treatments by in vivo studies 
is part of post-marketing surveillance [10]. Monitoring of ACT becomes particular important 
in the light of recent emergence of artemisinin resistance in South-East Asia [11-13]. In 
Liberia, the national treatment protocol for uncomplicated falciparum malaria was AS + AQ 
(separate tablets) since 2003, though only limited information was available on the efficacy 
of ACT in this highly malaria endemic country [14]. The present study assessed the in vivo 
efficacy of ASAQ FDC compared to that of artemether-lumefantrine in a non-inferiority trial 
among 300 children aged six to 59 months in Nimba County, a falciparum malaria endemic 
region in Northern Liberia. At the same site, both treatments were also studied in children 
over five years of age and adults in a parallel randomized trial with 28 days follow-up and the 
primary objective to obtain data on the safety and tolerability in this under-studied age group. 
The methods and findings of this second trial are reported in detail elsewhere [15] but a 
summary of efficacy results in the older age group are included here. 
Methods 
Study site, objectives and design 
An open-label, randomized non-inferiority trial was carried out between December 2008 
(first inclusion) and July 2009 (last scheduled follow up visit) in the Comprehensive 
Healthcare Center (CHC) of Saclepea, Nimba County. The facility was supported by 
Médecins Sans Frontières and the Ministry of Health and served the local population and 
displaced persons from Ivory Coast in a nearby refugee camp. The primary objective was to 
evaluate the efficacy of amodiaquine-artesunate versus artemether-lumefantrine among 
children between six and 59 months old suffering from uncomplicated malaria defined as the 
genotype adjusted cure rates at day 42 [10]. Secondary objectives were: (a) to evaluate the 
genotype- unadjusted cure rates at day 42, genotype adjusted/unadjusted cure rates at day 28, 
and re-infection rates at day 42; (b) to assess blood drug concentration differences possibly 
influencing efficacy by measuring drug concentrations of amodiaquine and lumefantrine at 
day 0 and day 7; (c) to assess the safety of amodiaquine-artesunate and artemether-
lumefantrine treatment among children between 6 and 59 months by documenting adverse 
events that occurred during the study before day 28 and by documenting serious adverse 
events; (d) to formulate recommendations for adapted case management of malaria in Nimba 
County. The findings on tolerability and safety (secondary objective (c)), are described in 
detail elsewhere [15]. 
Inclusion criteria were: age six to 59 months; fever (axillary temperature ≥ 37.5°C) or fever 
in previous 48 hours; blood smear-confirmed asexual stages of falciparum malaria (P. 
falciparum mono-infection) and parasite density between 2,000–200,000/µl blood; high 
probability of attending follow-up; signed informed consent (patient or responsible 
caregiver). Exclusion criteria were: severe/complicated malaria [16]; severe anaemia (<5 g/dl 
haemoglobin (Hb)); full course of AS + AQ or AL in the past 10 days; known 
hypersensitivity to the study drugs; concomitant febrile illness other than malaria that may 
confound outcome; severe malnutrition (weight-for-height < 70% of median and/or 
symmetrical edema involving at least the feet). Previous intake of anti-malarials other than 
AS + AQ or AL did not lead to exclusion from study participation, Study visits were on Days 
0, 1, 2, 3, 7, 14, 21, 28, 35 and 42. Patients were not routinely hospitalized for study 
participation unless required for treatment of any clinical presentations during study follow 
up. All routine measures that were performed during study visits are described below. 
Randomization, drug allocation and blinding 
Inclusion was between December 2008 and May 2009. Patients HRP-2 rapid diagnostic test-
positive (Paracheck®) were screened for inclusion by clinical examination, malaria blood 
smear, Hb measure (capillary blood, HemoCue®). Eligible patients were randomized at 1:1 
ratio to ASAQ or AL. Random allocation (computer-generated, block size of 6, study site 
unaware of block size) was provided in sealed, opaque individual envelopes which were 
opened in consecutive order by study nurses at drug allocation. Allocation was not disclosed 
to the medical staff performing the clinical exams, but different intake schedules of ASAQ 
and AL may have compromised full masking. The laboratory team was un-blinded to 
treatment allocation since blood spots for lumefantrine concentration assessment (AL arm) 
were collected on filter-paper pre-treated with tartaric acid. 
Treatment 
Treatment by study arm was on days 0, 1 and 2. ASAQ (ASAQ Winthrop®, Sanofi-Aventis) 
was given once a day without co-administration of food, though breast feeding for infants in 
the ASAQ arm around the time of drug intake was not discouraged. AL (Coartem®, 
Novartis) was given as two doses per day, 6–12 hours between doses, and administered with 
a high-fat cookie. For small children the cookie was given as a paste mixed with water or 
breast-feeding was encouraged. Both treatments were administered with a glass of water. For 
infants who could not swallow tablets, tablets were dissolved (ASAQ) or crushed and mixed 
(AL) with a small volume of water. Both treatments were three-day oral regimens dosed by 
weight according to the manufacturer’s instructions: ASAQ Winthrop® 5 to <9 kg: one 
tablet/day of artesunate (AS) 25mg/amodiaquine (AQ) 67.5mg; 9 to <18kg: one tablet/day of 
AS 50mg/AQ 135mg; 18 to <36kg: 1 tablet/day of AS 100mg/AQ 270mg; ≥36 kg: 2 
tablets/day of AS 100mg/AQ 270mg. Coartem® tablet strength was 20mg artemether/120mg 
lumefantrine: 5 to <15kg: 1 tablet/dose; 15 to <25kg: 2 tablets/dose; 25 to <35kg: 3 
tablets/dose; ≥ 35 kg 4 tablets/dose. The children’s weight was rounded to the nearest kg for 
dosing of the study drug. All doses were administered in the study site and observed for 30 
minutes. If vomited/spat-out within 30 minutes, a full-dose was re-administered. If again 
vomited/spat-out within 30 minutes, the patient was withdrawn and rescue treatment given 
(parenteral quinine or intramuscular artemether). In the event of treatment failure and in the 
absence of signs of severe malaria, patients in the AL arm were treated with ASAQ 
Winthrop, and patients in the ASAQ arm were treated with AL (administered with a fatty 
cookie) and terminated from further study follow-up. The first dose of rescue treatment was 
given in the study site, observed for 30 minutes and re-administered in case of vomiting. 
Blood smear follow up and parasite genotyping 
Giemsa-stained malaria thin and thick blood smears were prepared from capillary blood on 
days 0, 2, 3, 7, 14, 21, 28, 35 and 42. Trophozoites were counted against 500 white blood 
cells (WBCs) in the thick smear, assuming an average of 8000 WBCs / µl blood. For high 
parasitaemia, parasites were counted against 1000 red blood cells in the thin smear. 
Plasmodium species and parasite blood stages were differentiated on the thick smear in at 
least 30 high power fields, and confirmed on the thin smear. All blood smears were read by a 
second reader blinded to the first reader’s result. Readings of two readers in agreement were 
reported as final result. For discrepant slides the final reading was by the lab supervisor or a 
designated senior reader. External quality control (EQC) was performed by the Shoklo 
Malaria Research Unit (SMRU) in Mae Sot, Thailand, on 10% of all day 0 enrolment slides, 
10% of all day 2 slides, 10% of all negative follow-up slides and all failure slides. 
For each patient at enrolment, and on any follow up day with blood-smear-confirmed 
recurrent parasitaemia, two blood spots were prepared from capillary or venous blood (in 
EDTA) onto filter paper (Whatman FTA®cards) for parasite genotyping to distinguish 
between falciparum malaria recrudescence and re-infection, using three genetic markers 
(glurp, msp1, msp2) as described elsewhere [17]. In the second trial on the tolerability of 
ASAQ and AL among 1000 patients aged >5 years with uncomplicated falciparum malaria 
(1:1 randomized to ASAQ or AL, details reported elsewhere) the malaria blood smear follow 
up was limited to days 0, 2 and 28, day 3 if positive on day 2 [15], and any visit if fever. 
Clinical monitoring and laboratory follow up 
At each visit a standardized symptoms questionnaire and physical examination were 
conducted by trained study physician assistants. Vital signs (pulse rate, respiratory rate, and 
blood pressure) were recorded on day 0 and 28 for all patients. Fever was assessed at every 
visit by measuring the axillary temperature with a digital thermometer. Temperatures > 
37.5°C were recorded as fever. Haemoglobin (Hb) was measured on each visit (finger-prick 
capillary blood, HemoCue®), and liver function tests were conducted by assessment of blood 
levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (Reflotron 
plus®, Roche Diagnostics) on days 0 and 28. A full blood count (FBC) was done on days 0, 7 
and 28 (Act5diff, Beckman Coulter®), or if the HemoCue® result indicated anaemia (defined 
as <10 g/dl Hb for children < 2 years, <11 g/dl Hb for children > 2 years) [18]. Clinical- or 
laboratory signs and symptoms which occurred or worsened at any time after the first drug 
intake up to day 28 were recorded as adverse events (AEs) to document tolerability and 
safety (for details on adverse event recording and results [15]. 
Sample size 
The sample size calculation was based on an assumed efficacy of 96% for both ACTs, a non-
inferiority margin of 6%, a power of 80%, and a one-sided 5% significance level. To this end 
132 children per study arm were required (nQuery Advisor). With a 10% lost to follow up 
rate, the total number of children was rounded to 300 (150 per study arm). 
Efficacy outcome analysis 
Efficacy analyses were conducted on both mITT (modified-intention-to-treat) and PP (per 
protocol) populations. The mITT population was defined as all randomized patients with 
parasitological confirmation of falciparum malaria at day 0 who took at least one dose of 
study drug. The PP population was defined as all patients who were included into the mITT 
population and who did not have a major protocol deviation and who were not pre-maturely 
discontinued from the study for reasons other than an adverse event (AE) or recurrence of 
parasitaemia. Major deviations were defined as: i) at inclusion: weight < 5kg, no microscopic 
confirmation of asexual stages of Pf malaria or mixed infection, asexual parasites density < 
2,000 or > 200,000 /µl of blood, no fever (axillary temp > 37.5°C) or no history of fever in 
the last 48 hours, no informed consent, presence of general danger signs, signs of 
severe/complicated malaria, severe anaemia (Hb < 5g/dL), severe malnutrition (WH < 70%), 
having received a full course of the treatment under study in the previous 10 days; ii) during 
study conduct: any dose of study drug not taken or vomited and not replaced / or delayed by 
≥ 1 calendar date, two consecutive study visits not performed in the allowed time window 
[−1; +3 days], or intake of concomitant medication (except for anti-pyretics) during follow-
up if medication is of known anti-malarial activity. Results were reported by treatment group 
as allocated. Treatment outcomes were classified using standard definitions: adequate clinical 
and parasitological response (ACPR), early treatment failure (ETF), late parasitological 
failure (LPF), and late clinical failure (LCF) [10]. The main efficacy endpoints were day 42-
genotyping-adjusted cure rates. Secondary efficacy endpoints were genotyping-adjusted day 
28, and genotyping-unadjusted day 28 and day 42 efficacy outcome. Day 42 and day 28 cure 
rates were provided through estimates of survival by Kaplan-Meier (KM) analysis on the 
mITT population (mITT/KM), and by calculation of the proportion of patients cured by day 
28 or day 42, respectively, with the PP population (PP/%). Patients with recurrent 
parasitaemia and missing or inconclusive genotyping results were excluded from genotyping-
adjusted efficacy analyses and coded as failure for genotyping-unadjusted analyses 
(mITT/KM and PP/%) [10]. P. falciparum re-infections were censored at visit of recurrence 
for genotyping-adjusted mITT/ KM analysis, excluded from genotyping-adjusted PP/% 
analysis and coded as failure for all genotyping-un-adjusted analyses. Non-Pf malaria species 
infections were censored at visit of recurrence for mITT/KM analyses, and excluded from 
PP/% analyses.Pre-mature study discontinuations or patients with two consecutive scheduled 
visits not performed in the allowed time window [−1; +3 days] were censored at the last visit 
performed according to schedule for mITT/KM analysis. Pre-mature study discontinuation 
due AE were excluded from the PP/% analysis [10] (other premature discontinuations or 
patients with visits not performed in the allowed time window were already excluded from 
the PP population). 
All proportions/rates were presented with a 95% confidence interval (CI) by treatment group. 
For assessment of non-inferiority of ASAQ versus AL, a 90% CI was constructed around the 
day 42 genotyping-adjusted cure rate difference (AL- ASAQ), and the upper limit of the CI 
(= a one-sided 95% CI) was compared to the pre-set non-inferiority margin. In addition, the 
Kaplan-Meier estimated probability of remaining free of P. falciparum re-infection (re-
infection coded as failure, treatment failures or events without treatment outcome censored, 
patients with missing or undetermined genotyping excluded) was assessed per treatment arm 
and survival curves compared by log rank test. The median time to re-infection and 
interquartile range (IQR) per arm were assessed and the median compared using the 
Wilcoxon rank-sum test. The proportion of patients who achieved parasite clearance (asexual 
P. falciparum) on days 0, 2 and 3, and the proportion of patients with gametocytes on days 0, 
2, 7, 14 and 28 were assessed. Analyses were performed with STATA 10.1. (Stata Corp, 
Texas), following a pre-set statistical analysis plan. 
Anti-malarial blood concentrations 
Day 0 and day 7 blood concentrations of amodiaquine (AQ) and desethylamodiaquine 
(DEAQ) (ASAQ arm), or lumefantrine (LF) (AL arm), were assessed from venous blood 
(EDTA) preserved as dried spots on filter paper (Whatman® 31 ET). For LF samples the 
filter paper was pre-treated with tartaric acid (0.75 µM) and stored refrigerated [19]. Blood 
spots were sent once per month to the pharmacology laboratory in Paris and stored at −80°C 
until analysis. AQ, DEAQ and LF blood concentrations were measured by high performance 
liquid chromatography with ultraviolet detection (LF) or by tandem-mass spectrometry 
(AQ/DEAQ) with limits of quantification (LOQ) of <2.5 ng/ml (AQ), <5.0 ng/ml (DEAQ), 
and <200 ng/ml (LF), respectively. Day 7 samples collected before day 6 or after day 8 were 
excluded from statistical analysis on blood concentrations. Summary statistics were provided 
(mITT population), and comparison of day 7 blood concentrations between patients with day 
42 efficacy outcome ACPR versus recrudescence, or ACPR versus re-infections, or ACPR 
versus combined P. falciparum recurrences (re-infection, recrudescence and recurrences with 
missing or undetermined genotyping results) respectively, performed (mITT, comparison by 
Wilcoxon rank-sum test). Furthermore, day 0 blood concentrations of other anti-malarials: 
pyrimethamine, sulfadoxine, chloroquine, quinine were retrospectively assessed from stored 
serum samples collected at baseline from each patient. Concentrations measures were by 
liquid chromatography coupled with tandem mass spectrometry, after protein precipitation by 
acetonitrile containing hydroxychloroquine as internal standard [20]. 
Ethics 
The procedures followed were in accordance with the ethical standards of the Helsinki 
Declaration. All participants or responsible caretakers signed informed consent. The studies 
were approved by the Liberian Institute for Biomedical Research (LIBR) Ethics committee, 
the Ministry of Health and Social Welfare, Monrovia, Liberia, and the Comité de Protection 
des Personnes (CPP) Ile de France XI (Saint Germain en Laye), France. The studies were 
registered at Controlled Trials (http://www.controlled-trials.com/. ISRCTN51688713, 
ISRCTN40020296). 
Results 
Inclusion, baseline characteristics and follow-up 
A total of 701 pre-screened patients were checked for eligibility, and 300 children were 
included and randomized to the two arms (Figure 1). Demographics and baseline 
parasitological- and clinical parameters were similar between the treatment arms (Table 1). 
The distribution of patients’ weight and age by weight-based drug dosage group and study 
arm are provided in Additional file 1. All randomized patients had been exposed to at least 
one dose of the study drug. All but one patient (ASAQ arm) who participated twice (second 
participation excluded from all analyses) were included to the mITT population (n = 149 
ASAQ, n = 150 AL) (Figure 1). Ninety-six-point-six percent (144/149) of patients (ASAQ, 
mITT) and 86.7% (130/150) of patients (AL, mITT), completed the study treatment 
according to schedule (no delay ≥ 1 calendar day, no dose missed). Delayed dose intake was 
recorded in the AL arm for 8.7% of patients (13/150, one or two doses delayed by one 
calendar day). The treatment of these patients was completed on day 3. Few patients had 
incomplete treatment: 3.4% (5/149, ASAQ) and 4.7% (7/150 AL) respectively. This was 
either due to premature study-discontinuation (1/149 ASAQ incorrect enrolment; 1/150 AL 
repeated vomiting of dose, SAE), missed visits for dose-intake (2/150 AL, n = 1 one evening 
dose missed, n = 2 two evening doses missed), or spitting-out/wasting (part) of a dose (4/149 
ASAQ arm; 4/150 AL arm). Ninety-two patients (61.7%, ASAQ) and 104 patients (69.3%, 
AL) completed 42 days of follow-up. Premature study discontinuations were mainly due to 
recurrent parasitaemia before day 42 (Figure 1). No patient was lost to follow-up, two 
caregivers had withdrawn consent for two participating children (day 3 and day 21, 
respectively, AL). Three patients were prematurely discontinued due to a serious adverse 
event (SAE): one severe pneumonia (day 3, ASAQ), one severe malaria (P. falciparum re-
infection, day 30, ASAQ), and one severe vomiting (onset severe vomiting on day 1, 
withdrawn and hospitalized after repeated vomiting of day 1 evening study dose, AL). All 
SAEs had outcome fully recovered. Major protocol deviations and pre-mature study 
discontinuations other than AE or recurrence of parasitaemia lead to exclusion from the per-
protocol population for seven (4.7%, ASAQ) and 24 (16%, AL) patients, respectively (Figure 
1). 
Figure 1 Trial profile with mITT and PP populations. RDT = rapid diagnostic test for 
malaria (Paracheck® ); Pf = Plasmodium falciparum; WH = Weight for Height; mITT = 
modified Intention to Treat; KM = Kaplan Meier; SAE = Serious Adverse Event; PP = Per 
Protocol. a Second participation excluded from analyses.* Note: one patient was discontinued 
with recurrent malaria (Pf re-infection, day 30). This patient is listed here among the n = 2 
patients pre-maturely discontinued due to SAE (severe malaria). ** Patient was discontinued 
from participation on day0 shortly upon enrolment because eligibility criteria were not met: 
i.e. asexual parasites density was outside the eligibility range (< 2000 or > 200 000 / µl 
blood). *** Two patients were enrolled with day 0 asexual parasites density outside the 
eligibility range (< 2000 or > 200 000 / µl blood): n = 1 patient was discontinued on day0, 
once the eligibility error was discovered (discontinuation due to incorrect enrolment); n = 1 
patient continued the follow-up to day 42. Both patients were excluded from the per-protocol 
population (protocol deviation). # Pre-mature discontinuations other than discontinuations due 
to adverse event or recurrence of parasitaemia which lead to exclusion from the PP 
population. ## For n = 1 patient the care-taker withdrew consent on day 3; for n = 1 patient the 
care-taker withdrew consent on day 21. ### n = 1 patient who also missed 2 evening doses is 
not listed among these n = 19, since the primary reason for exclusion of this patients from PP 
population was withdrawal of consent by care-taker (day 3) (patient listed among n = 2 
consent withdrawn). 
Table 1 Demographic and parasitological baseline characteristics by treatment arm, 
mITT population 
 ASAQ AL 
N = 149 N = 150 
Sex (male), N (%) 86 (57.7) 89 (59.3) 
Age (months), mean (sd) 37.2 (13.7) 37 (13.6) 
Weight (kg), mean (sd) 12.8 (2.5) 12.9 (2.6) 
Axillary temperature (°C), mean (sd) 37.1 (1.1) 36.9 (0.8) 
Haemoglobin (g/dl) *, mean(sd) 9.2 (1.6) 9.3 (1.5) 
P. falciparum trophozoites/µl, geometric mean, (95%CI) 20020 19152 
(15878–25244) (15386–23839) 
P. falciparum trophozoite density/µl, N (%)   
  < 2,000 0 0 
 2,000 - < 50,000 105 (70.5) 113 (75.3) 
 50,000 - < 100,000 21 (14.1) 22 (14.7) 
 100,000 - < 150,000 15 (10.1) 8 (5.3) 
 150,000 - < 200,000 6 (4.0) 7 (4.7) 
  > 200,000 2 (1.3) 0 
P. falciparum gametocytes carriage, N (%) 22 (14.8) 22 (14.7) 
Sd = standard deviation, CI = confidence interval. * Hb measures by Act5diff, Beckman Coulter®. 
Primary efficacy outcomes 
Treatment outcomes and endpoint classifications for efficacy analyses are displayed in Table 
2 (mITT/KM analysis) and Table 3 (PP/% cured analysis). One patient in the ASAQ arm and 
three in the AL arm experienced treatment failure up to day 28, amounting to a total of three 
(ASAQ) and six (AL) failures by day 42 (Table 2) (mITT). All treatment failures were LPFs 
(days 21–42) with exception of one ETF (day 2, AL). All failures had completed the study 
treatment according to schedule, except one LPF (skipped both day 1 doses, completed 
regimen on day 3, AL arm). Among patients with recurrent parasitaemia, seven had missing 
or inconclusive genotyping results (n = 2 ASAQ; n = 5 AL) (excluded from genotyping-
adjusted analyses). The day 42 genotyping-adjusted cumulative cure rate estimate (mITT/ 
KM) was 97.3% [CI95%: 91.6-99.1] (ASAQ) and 94.2% [88.1-97.2] (AL), respectively 
(Figure 2A, Table 4). The cure rate difference (AL-ASAQ) was −3.1% with an upper limit 
95%CI of 1.2%, demonstrating non-inferiority of ASAQ to AL. Results were similar for 
percentage cured on the PP population (PP/%)(Table 4). 
Table 2 Efficacy endpoint classification at day 28 and day 42, - mITT / KM analysis 
Treatment outcome Day28 Day42 
mITT population, N (%) ASAQ AL ASAQ AL KM analysis 
N = 149 N = 150 N = 149 N = 150 
ACPR 104 (69.8) 123 (82.0) 77 (51.7) 82 (54.7) success 
ETF 0 1 (0.7) 0 1 (0.7) failure 
LCF or LPF      
- P. falciparum recrudescence 1 (0.7) 2 (1.3) 3 (2.0) 6 (4.0) failure 
- P. falciparum re-infection 39 (26.2) 13 (8.7) 64 (43.0) 45 (30.0) censored* 
- undetermined or missing PCR 2 (1.3) 2 (1.3) 2 (1.3) 5 (3.3) excluded* 
Non-P. falciparum malaria infection ** 0 3 (2.0) 0 5 (3.3) censored 
No treatment outcome      
- discontinued for SAE # 1 (0.7) 1 (0.7) 1 (0.7) 1 (0.7) censored 
- withdrawal after incorrect enrolment ## 1 (0.7)  1 (0.7)  censored 
- unable to complete follow-up visits  1 (0.7)  1 (0.7) censored 
- withdrawal of consent  2 (1.3)  2 (1.3) censored 
- ≥ 2 consecutive visits not performed 1 (0.7) 2 (1.3) 1 (0.7) 2 (1.3) censored 
Patients analysed      
Genotyping-adjusted analysis N = 147 N = 148 N = 147 N = 145  
Genotyping-unadjusted analysis N = 149 N = 150 N = 149 N = 150  
mITT = modified Intention To Treat; KM = Kaplan-Meier; PP = per protocol; ACPR = Adequate 
Clinical and Parasitological Response; ETF = Early Treatment Failure; LPF=Late Parasitological 
Failure; LCF = Late Clinical Failure; PCR = Polymerase Chain Reaction; SAE = Serious Adverse 
Event. 
* coded as Failure in genotyping -un-adjusted analysis. 
** Plasmodium malariae infections. 
#
 n=1 patient with SAE (= severe malaria due to re-infection with Pf malaria, ASAQ, day 30) is not 
listed here among SAE, but instead listed among the re-infections (= efficacy endpoint). 
##
 n=1 withdrawn following incorrect enrolment on day 0 (=asexual parasites density outside the 
eligibility range). 
Table 3 Efficacy endpoint classification at day 28 and day 42, - PP / percent cured 
analysis 
Treatment outcome Day28 Day42 
PP population, N (%) ASAQ AL ASAQ AL % cured analysis 
N = 142 N = 126 N = 142 N = 126 
ACPR 99 (69.7) 108 (85.7) 75 (52.8) 71 (56.3) success 
ETF 0 (0) 1 (0.8) 0 (0) 1 (0.8) failure 
LCF or LPF      
- P. falciparum recrudescence 1 (0.7) 2 (1.6) 3 (2.1) 5 (4.0) failure 
- P. falciparum re-infection 39 (27.5) 11 (8.7) 61 (43.0) 40 (31.7) excluded* 
- undetermined or missing PCR 2 (1.4) 2 (1.6) 2 (1.4) 5 (4.0) excluded* 
Non-P. falciparum malaria infection ** 0 (0) 2 (1.6) 0 (0) 4 (3.2) excluded 
No treatment outcome      
- discontinued for SAE 1 (0.7) 0 (0) 1 (0.7) 0 (0) excluded 
Patients analysed      
Genotyping-adjusted analysis N = 100 N = 111 N = 78 N = 77  
Genotyping-unadjusted analysis N = 141 N = 121 N = 141 N = 122  
mITT = modified Intention To Treat; KM = Kaplan-Meier; PP = per protocol; ACPR = Adequate 
Clinical and Parasitological Response; ETF = Early Treatment Failure; LPF = Late Parasitological 
Failure; LCF = Late Clinical Failure; PCR = Polymerase Chain Reaction; SAE = Serious Adverse 
Event. * coded as Failure in genotyping-unadjusted analysis. ** Plasmodium malariae infections. 
Figure 2 Kaplan-Meier survival curves. Modified intention to treat (mITT) population. Full 
line (ASAQ arm), dashed line (AL arm). (A) genotyping-adjusted probability to be cured. (B) 
probability to remain free of re-infection. 
Table 4 Genotype adjusted and non-adjusted day 28 and day 42 cure rates, and day 42 
non-inferiority analyses 
 KM cure rate estimates Observed proportion cured 
mITT population PP population 
Day28 ASAQ AL ASAQ AL 
Genotyping-adjusted 
Patients analysed% cured 
[95%CI] 
N = 147 
99.3 [95.1-99.9] 
N = 148 
97.9 [93.6-99.3] 
N = 100 
99.0% [94.6-100] 
N = 111 
97.3% [92.3-99.4] 
Genotyping-unadjusted 
Patients analysed% cured 
[95%CI] 
N = 149 
71.2% [63.1- 77.9] 
N = 150 
87.5% [80.9-91.9] 
N = 141 
70.2% [61.9-77.6] 
N = 124 
87.1% [79.9-92.4] 
Day42 
Genotyping-adjusted 
Patients analysed% cured 
[95%CI] 
N = 147 
97.3 [91.6-99.1] 
N = 145 
94.2 [88.1-97.2] 
N = 78 
96.2% [89.2-99.2] 
N = 77 
92.2% [83.8-97.1] 
% difference # (UL 95%CI*) −3.1 (1.2) −3.9 (2.2) 
Genotyping-unadjusted 
Patients analysed% cured 
[95%CI] 
N = 149 
52.7% [44.3-60.5] 
N = 150 
59.5% [50.9-67.1] 
N = 141 
53.2% [44.6-61.6] 
N = 122 
58. 2% [48.9-67.1] 
#
 Percent difference in day42 genotyping-adjusted cure rate: AL arm day42% cured- ASAQ arm 
day42% cured. * According to the method of Blackwelder: one-sided 95% upper limit (UL) CI of a 
two-sided 90% CI around the difference of efficacy of cure rates. The CI was assessed by Wald 
method. 
Secondary efficacy outcomes 
Day 28 genotyping-adjusted cure rate estimates were 99.3% [95.1-99.9] (ASAQ) and 97.9% 
[93.6-99.3] (AL) (mITT/KM) (Table 4). Genotyping-unadjusted cure rates were 71.2% [63.2-
77.9] (ASAQ) and 87.5% [80.9-91.9] (AL) at day 28, and 52.7% [44.3-60.5] (ASAQ) and 
59.5% [50.9-67.1] (AL) at day 42 (mITT/ KM) (Figure 2b), respectively. Comparable results 
were obtained in PP/% analysis (Table 4). The Kaplan Meier estimated probability to remain 
free of re-infection was 0.55 [95%CI 0.46-0.63] in the ASAQ arm and 0.66 [0.57-0.73] in the 
AL arm (log-rank test, p = 0.017) (Figure 2B). The median time to re-infection was 29 days 
(mITT, ASAQ arm, IQR: 24–36) and 36 days (mITT, AL arm, IQR: 29–43) (p < 0.001). 
Results on PP population were similar. Day 2 parasite clearance was 98% in both treatment 
arms (145/148 ASAQ; 146/149, AL), and reached 100% (147/147, ASAQ) and 99.3% 
(148/149, AL) by day 3 (mITT population). One patient remained parasitaemic on day 3 
(ETF, AL). Gametocyte carriage peaked on day 2 with 22.3% (33/148, ASAQ) and 18.12% 
(27/149) and decreased to 2.4% (3/127, ASAQ) and 0.7% (1/139, AL) by day 28 (mITT) 
(Figure 3). Among patients who had no gametocytes at baseline, gametocyte carriage also 
peaked on day 2 and declined to 0.9% (1/108, ASAQ) and 0% (0/117, AL) by day 28 (Figure 
3). The day 28 genotyping-adjusted cure rates among patients >5 years (parallel tolerability 
trial) were 98.4% [96.7-99.2] (ASAQ) and 100% (AL) (mITT/KM), and 98.3% [97.0 – 99.5] 
(ASAQ) and 100% (AL) (PP/% cured), respectively. Few patients had presented with fever 
(> 37.5 °C) at enrolment (n = 49 ASAQ arm, n = 29 [15] AL arm, mITT population). For the 
majority of children history of fever in the last 48 hours before enrolment was reported. 
Among patients with fever on day 0 in the ASAQ arm, 98% were fever-free on day 1 and 2, 
and 100% fever-free on day 3. Fever clearance in the AL arm was 100% by day 1. 
Figure 3 Pf Gametocyte carriage by malaria blood smear up to day28, by treatment 
arm. Pf = Plasmodium falciparum. (A) Percentage of patients with Pf gametocytes by blood 
smear among total patients by follow up day, by treatment arm, mITT population. (B) 
Percentage of patients with Pf gametocytes by blood smear among patients who had no 
gametocytes on day0, by follow up day, by treatment arm, mITT population. 
Day 7 blood concentrations of AQ, DEAQ, LF 
Blood concentrations of amodiaquine (AQ), desethylamodiaquine (DEAQ) (ASAQ arm) and 
lumefantrine (LF) (AL arm) were assessed from day 0 (baseline) and day 7 blood samples. 
Amodiaquine-intake shortly before study inclusion (protocol violation) was evident for six 
patients (ASAQ arm) who had quantifiable day 0 AQ levels (range: 3.6 – 34 ng/ml). Three of 
these had also high DEAQ levels (>200 ng/ml). Seventy-eight patients had low DEAQ blood 
concentrations on day 0 (range: 5.0 -142 ng/ml), indicating a previous treatment with AQ (no 
violation). On day 7, three patients had DEAQ values below the LOQ (<2.5 ng/ml), 
suggestive of sub-optimal drug intake or mal-absorption. All three patients had completed the 
drug intake according to schedule and had day 42 efficacy outcome ACPR. Five patients also 
had detectable AQ on day 7, indicative of AQ intake before sample collection (protocol 
violation) (range: 2.6-4.2 ng/ml). No LF blood concentrations were detected in the AL arm at 
baseline. On day 7, 33 patients had non-quantifiable LF concentrations (< LOQ, 200 ng/ml). 
These were set as 100 ng/ml (=LOQ/2) by convention for all blood concentration analyses, 
since the LOQ was considered very high. 
The median day 7 DEAQ blood concentration of all patients in the ASAQ arm was 423 ng/ml 
(IQR 314, 602; 137/149 samples available and quantifiable, mITT). The median day 7 LF 
concentration was 310 ng/ml (IQR 200, 447;139/150 samples available and quantifiable, 
mITT, AL arm). The recrudescences in the ASAQ arm had day 7 DEAQ blood 
concentrations of 242, 401 and 688 ng/ml, respectively. Recrudescences in the AL arm had 
day 7 LF concentrations of 271, 447 and 515 ng/ml, respectively (n = 1 no sample available, 
n = 1 LF < LOQ). Comparison of day 7 blood concentrations between patients with day 42 
efficacy outcome ACPR versus recrudescence revealed no significant differences for DEAQ 
(ASAQ arm, p = 0.641) or LF (AL arm, p = 0.775), respectively (Table 5). Similarly, 
comparison of day 7 DEAQ drug concentrations between ACPR versus re-infections or 
ACPR versus all P. falciparum recurrences combined were not significantly different (ASAQ 
arm: p = 0.209, p = 205, Table 5). Day 7 LF blood concentrations were significantly lower in 
patients with re-infection (p = 0.022) or in patients with any type of P. falciparum 
recurrences (p = 0.015) when compared to ACPRs (AL arm, Table 5). Similar results were 
obtained when blood concentrations of patients with indication of recent AQ intake on day 0 
or day 7 (protocol violation) or low DEAQ on day 7 (ASAQ arm), and patients with day 7 LF 
values < LOQ (AL arm) were excluded from all day 7 blood concentration comparison 
analyses. 
Table 5 Day 7 desethylamodiaquine- and lumefantrine blood concentrations by day 42 
efficacy outcome and treatment arm (mITT) 
Study 
arm 
Compound Patients 
n/N # 
Day 42 Efficacy endpoint Blood concentrations 
[ng/ml] median (IQR) 
Wilcoxon rank-sum 
(Mann–Whitney) 
test ε 
ASAQ DEAQ 73/77 ACPR 456 (167, 1727)  
3/3 recrudescence1 402 (242, 688) p = 0.641 
59/64 P. falciparum re-infection 410 (308, 525) p = 0.209 
2/2 Recurrence with un-
determined or missing PCR 
525 (277, 772)  
64/69 Recurrences combined2 407 (303, 525) p = 0.205 
AL LF * 80/82 ACPR 356 (221, 547)  
4/6 recrudescence1 359 (186, 481) p = 0.775 
43/45 P. falciparum re-infection 295 (200, 363) p = 0.022 
5/5 Recurrence with un-
determined or missing PCR 
254 (100, 262)  
52/56 Recurrences combined2 276 (150, 373) p = 0.015 
#
 n = Number of patients with blood concentration sample available and quantifiable among total N. 
* n = 33 day 7 LF values were < LOQ. Values were set as LOQ/2 (=100 ng/ml). 
1
 Recrudescence = LPF + LCF. 
2
 Recurrences combined = Recrudescence, re-infection and recurrence with undetermined or missing 
PCR combined. 
ε Comparison between day 7 drug concentrations of patients with day 42 efficacy outcome ACPR 
versus recrudescence, ACPR versus re-infection, ACPR versus Pf recurrences combined. 
AQ = amodiaquine; LF = lumefantrine; DEAQ = desethylamodiaquine; mITT = modified Intention 
To Treat population; ACPR = Adequate Clinical and Parasitological Response; Pf = Plasmodium 
falciparum; PCR = Polymerase Chain reaction. 
Day 0 blood concentrations of other anti-malarials 
Stored day 0 serum samples were retrospectively analysed for detectable concentrations of 
other anti-malarials (Table 6, mITT population). At baseline 17% (ASAQ arm) and 10% (AL 
arm) of children had detectable concentrations of chloroquine, 8.1% (ASAQ) and 4.0% (AL) 
had detectable concentrations of sulphadoxine, 2% (ASAQ) and 4.7% (AL) had detectable 
quinine, and 1.3% (ASAQ) and 0.7% (AL) had detectable pyrimethamine, respectively. 
Median drug concentrations are tabulated (Table 6). 
Table 6 Day 0 serum concentration of other anti-malarial drugs, mITT population 
Study arm ASAQ N = 149* AL N = 150 
Antimalarial drug detected Patients Serum concentration 
[ng/ml] median (range) 
Patients Serum concentration 
[ng/ml] median (range) n (%) n (%) 
Pyrimethamine 2 (1.3) 73 (10–135) 1 (0.7) 408 (408) 
Sulphadoxine 12 (8.1) 49 (12–74323) 6 (4.0) 148 (22–123598) 
Chloroquine 25 (16.9) 127 (10–559) 15 (10.0) 82 (11–572) 
Quinine 3 (2.0) 32 (13–39) 7 (4.7) 413 (13–8511) 
*samples available for 148 of 149 patients. 
Discussion 
Since 2003, AS + AQ loose dose has been adopted as first-line treatment for uncomplicated 
falciparum malaria in Liberia. Published information on the efficacy of AS + AQ or other 
forms of ACT in the country are currently limited to only one observational study on the 
efficacy of artemether-lumefantrine in Tubmanburg and Harper region [14]. We report here 
on the in vivo efficacy of two ACTs, ASAQ fixed-dose-combination (FDC) and artemether-
lumefantrine (AL) among 6–59 month old children with uncomplicated falciparum malaria in 
Nimba County, a highly Pf malaria endemic area in Northern Liberia. The day 42 
genotyping-adjusted cure rate estimates of ASAQ and AL reached 97.3% and 94.2% 
respectively (mITT / KM). Both treatments were well above the WHO-recommended 90% 
threshold for treatments in use [10]. ASAQ FDC was shown to be non-inferior to AL after 42 
days of follow up in two parallel analytic approaches. Few treatment failures were detected, 
but > 50% occurred after day 28 in both study arms, arguing for 42 days follow up when 
monitoring these two treatments. In the parallel tolerability trial conducted among patients > 
5 years, an age group likely partially immune, day 28 genotyping-adjusted cure rates of 
ASAQ and AL were also high (> 95%). Though the limited malaria blood smear follow up in 
this second trial should be considered. Both ASAQ and AL were also well tolerated among 
children six to 59 month and among the older age group (>5 years), as described elsewhere in 
more detail [15]. 
Overall, efficacy results obtained in the present studies were very good for both ACTs. This 
was also encouraging for the utility of ASAQ FDC in a geographical setting where 
amodiaquine monotherapy and AS + AQ (non fixed formulation, i.e. blister packs) were used 
for several years. Notably however, anecdotal reports suggested that the prescription of AS + 
AQ loose dose provided the opportunity to disregard the amodiaquine compound, referring to 
patients’ and providers’ concern on tolerability related to prescriptions of higher dose 
amodiaquine monotherapy in the past [21]. The present findings were also in line with 
efficacy results recently reported for ASAQ FDC and AL in Western-, Central- and Southern 
African regions or India [6-9,22-24]. A recent study also demonstrated good effectiveness of 
both ASAQ FDC and AL among children ≤ 5 years following unobserved treatment in Benin 
[25]. Taken together these findings also open the possibility of using several efficacious and 
well tolerable forms of ACT in the same country, which may decrease drug pressure. As anti-
malarial drug efficacy may vary within regions and even within countries, ideally therapeutic 
efficacy studies would be performed regularly at representative sentinel sites if this is 
feasible. 
The proportion of parasitaemic patients on day 3 has been reported as an interesting indicator 
for monitoring artemisinin resistance [26]. Although this indicator requires large sample sizes 
and accurate timing of sample collection for precise estimates and is dependent on pre-
treatment parasite density, the low proportion of patients parasitaemic at day 3 for both 
ASAQ and AL in the present study was nevertheless reassuring. The use of more accurate 
estimations of parasite clearance rates with recently developed tools should be preferred but 
demand repeated parasitaemia measures [27]. Since sub-optimal drug exposure is considered 
among the main reasons for treatment failure, the day 7 blood concentration of the slowly 
eliminated artemisinin-partner drugs was proposed as a simplified and valid pharmacokinetic 
predictor of treatment outcome [28]. Day 7 DEAQ or LF bloods concentrations in the present 
study were overall close to those reported in two previous studies using whole blood samples 
on filter paper [19,29]. No evidence was found that treatment failure in either study arm was 
linked with inadequate drug exposure when comparing day 7 DEAQ or LF drug levels, 
respectively, among patients with ACPR versus recrudescence. The comparison for 
recrudescences was however limited by the few treatment failures. Notably day 7 LF 
concentrations were significantly lower among patients with re-infection than among patients 
with ACPR, while this was not the case for day 7 DEAQ concentrations. No direct 
correlation between day 7 drug levels and re-infection has been established yet, and 
additional measurements beyond day 7 would be needed for a more robust analysis of a 
potential correlation. Fever clearance was good in both treatment arms among the few 
children who had presented with temperatures >37.5°C on day 0. Gametocyte carriage was 
reduced significantly during follow up. It seemed slightly slower in the ASAQ arm than in 
the AL arm, as indicated mainly by a higher percentage of gametocyte carriage on day 7. 
The overall P. falciparum re-infection rate was high in the present study, emphasizing the 
burden of malaria among the non-immune < 5 year olds in Nimba County. Re-infection rates 
were higher in the ASAQ arm than the AL arm, and AL conferred a longer secondary 
prophylactic effect than ASAQ with a significantly lower median time to re-infection in the 
ASAQ arm. The current WHO treatment protocol emphasizes the curative effect of the anti-
malarial treatment, i.e. a fast elimination of the parasite [2]. A potentially increased risk of 
resistance development has also been discussed for artemisinin partner compounds that 
confer longer post-treatment prophylaxis [30,31], and the benefit of the prophylactic effect of 
an anti-malarial may also need to be compared against other essential elements, such as fast 
parasite elimination, good tolerability, easy administration and good compliance. 
In 2001 high resistance to chloroquine and sulphadoxine-pyrymethamine (SP), the respective 
first- and second-line treatments in the country at the time, were reported in the Harper 
region, Liberia [32]. A second study showed that amodiaquine (AQ) monotherapy still had 
relatively good efficacy [32,33]. In 2003, AS-AQ combination therapy (provided as co-
blister-packed separate tablets) was adopted as first-line treatment for uncomplicated 
falciparum malaria in Liberia. Non-ACT, such as chloroquine and amodiaquine are however 
still available and used by the population in Liberia [21,34]. In the present study, assessment 
of day 0 serum concentrations of various anti-malarials indicated that a considerable 
proportion of children had recent anti-malarial intake, mainly chloroquine and sulphadoxine. 
These findings are not unexpected in a highly endemic setting, and are unlikely to have 
impacted much on the efficacy results. However, ongoing use of non-ACT, including 
chloroquine which can evoke cross-resistance to amodiaquine, re-emphasizes the need to 
ensure wide–spread and continuous access to the first-line ACT while removing access and 
use of non-ACT. Following the introduction of ASAQ FDC as first-line treatment in 2010, 
the most recent Liberian Malaria Indicator survey conducted in 2011 reported that for about 
seven out of 10 children who received an anti-malarial treatment, caretakers indicated the use 
of an ACT (referring to “the new malaria medicine”, i.e. ASAQ FDC) [21]. These findings 
are encouraging and should be supported with ongoing efficacy monitoring. 
Conclusion 
ASAQ and AL were both highly efficacious treatments for uncomplicated falciparum malaria 
in Nimba County. These findings support both drugs as treatment options. Since the end of 
2010, ASAQ FDC was adopted as national first-line treatment in Liberia. As for all malaria 
endemic settings, anti-malarial treatment monitoring should continue on a regular basis, 
ideally including recently developed early indicators of emerging artemisinin resistance. 
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